Menu Search
Equities

Equasens SA

EQS:PAR

Equasens SA

Actions
TechnologyTechnology
  • Price (EUR)46.75
  • Today's Change-3.25 / -6.50%
  • Shares traded43.88k
  • 1 Year change-30.84%
  • Beta0.7291
Data delayed at least 15 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in EUR

The 3 analysts offering 12 month price targets for Equasens SA have a median target of 81.00, with a high estimate of 105.00 and a low estimate of 64.30. The median estimate represents a 73.26% increase from the last price of 46.75.
High124.6%105.00
Med73.3%81.00
Low37.5%64.30

Dividends

In 2023, Equasens SA reported a dividend of 1.25 EUR, which represents a 8.70% increase over last year. The analyst covering the company expects dividends of 0.90 EUR for the upcoming fiscal year, a decrease of 28.00%.
Div growth (TTM)8.70%
More ▼

Earnings history & estimates in EUR

Equasens SA reported annual 2023 earnings of 3.13 per share on Mar 29, 2024.
Average growth rate+13.88%
More ▼

Revenue history & estimates in EUR

of 57.00m. This missed the 59.10m estimate of the one analyst following the company.
Average growth rate-0.99%
Pharmagest Interactive SA had revenues for the full year 2023 of 219.70m. This was 2.63% above the prior year's results.
Average growth rate+8.56%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.